Researchers will be on the show site to collect free-catch urine samples. Please support this important research!!
John Robertson VMD PhD, President, Rametrix Technologies, Inc., Blacksburg, VA
Rametrix Technologies, Inc., a medical/veterinary research and development company (www.rametrixtech.com), has developed a urine-based technology (RMU) to detect cancer in dogs (and people). Ramen spectroscopy profiles the molecular composition of urine, and the team has published a paper showing detection in dogs of lymphoma, mast cell sarcoma, urothelial/transitional cell carcinoma, and osteosarcoma with at least 90% accuracy using RMU technology (available at https://rametrixtech.com/resources/).
This technology uses a small amount of free-catch/voided urine, takes less than 30 minutes, and is economical (about the same price as a standard urinalysis at the veterinarian’s office). Studies conducted in humans have also detected other diseases such as diabetic nephritis, lupus nephritis, chronic kidney failure, and bladder cancer. Rametrix will use this translational information gained from humans in the proposed work on Golden Retriever health.
To further validate RMU and to precisely focus it for Goldens, Rametrix wants to conduct a 500-dog study (250 healthy dogs, 250 dogs with cancer or other health problems, including kidney disease) with cooperation of the Golden Retriever Club of America. Study goals:
Ultimately, early detection of disease may alleviate suffering and save lives.
Note: Since this is a research study and the meaning of individual results is not yet fully validated, no results will be released to owners.
